New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.

Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.

Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.